Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Ardelyx Inc (ARDX)

Ardelyx Inc (ARDX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,423,816
  • Shares Outstanding, K 242,972
  • Annual Sales, $ 333,620 K
  • Annual Income, $ -39,140 K
  • EBIT $ -38 M
  • EBITDA $ -36 M
  • 60-Month Beta 0.66
  • Price/Sales 4.25
  • Price/Cash Flow N/A
  • Price/Book 9.18

Options Overview Details

View History
  • Implied Volatility 87.09% ( +16.40%)
  • Historical Volatility 71.04%
  • IV Percentile 77%
  • IV Rank 47.93%
  • IV High 131.92% on 12/17/24
  • IV Low 45.81% on 08/21/25
  • Put/Call Vol Ratio 0.09
  • Today's Volume 240
  • Volume Avg (30-Day) 1,310
  • Put/Call OI Ratio 0.37
  • Today's Open Interest 79,375
  • Open Int (30-Day) 78,610

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 0.02
  • Number of Estimates 6
  • High Estimate 0.06
  • Low Estimate -0.02
  • Prior Year 0.02
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.91 +19.47%
on 10/17/25
6.73 -12.93%
on 10/31/25
+0.85 (+16.97%)
since 10/14/25
3-Month
4.71 +24.41%
on 10/13/25
6.78 -13.57%
on 09/11/25
+0.02 (+0.34%)
since 08/14/25
52-Week
3.21 +82.55%
on 05/15/25
6.78 -13.57%
on 09/11/25
+1.15 (+24.42%)
since 11/14/24

Most Recent Stories

More News
Real-World Evidence Studies of XPHOZAH® (tenapanor) Demonstrate Patient Satisfaction and Reduction in Serum Phosphate with XPHOZAH in Data Presented at ASN Kidney Week

WALTHAM, Mass., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines...

ARDX : 5.86 (+0.51%)
Ardelyx to Participate at the Jefferies Global Healthcare Conference in London

WALTHAM, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines...

ARDX : 5.86 (+0.51%)
Ardelyx President and Chief Executive Officer Mike Raab to Participate in the Wedbush Rewind American Society of Nephrology 2025 Investor Conference

WALTHAM, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines...

ARDX : 5.86 (+0.51%)
Ardelyx: Q3 Earnings Snapshot

Ardelyx: Q3 Earnings Snapshot

ARDX : 5.86 (+0.51%)
Ardelyx Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Q3 2025 product revenue of $105.5 million reflects 15% year-over-year growth IBSRELA ® Q3 revenue of $78.2 million reflects 92% year-over-year growth; IBSRELA guidance raised, 2025 revenue expected...

ARDX : 5.86 (+0.51%)
Ardelyx Presents Data that Continues to Support the Benefits of IBSRELA® (tenapanor) at the American College of Gastroenterology’s 2025 Annual Meeting

IBSRELA patients reported treatment satisfaction in real-world survey Post-hoc analysis of T3MPO-1 and T3MPO-2 studies demonstrates effectiveness of IBSRELA in reducing abdominal bloating for patients...

ARDX : 5.86 (+0.51%)
Ardelyx Announces Four Abstracts Accepted for Poster Presentations at the American Society of Nephrology’s Kidney Week

WALTHAM, Mass., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines...

ARDX : 5.86 (+0.51%)
2 Overlooked Stocks to Snap Up in 2025

While much of Wall Street’s attention in 2025 centers around AI names, two under-the-radar companies are quietly getting stronger.

TCRX : 1.1000 (-2.65%)
ARDX : 5.86 (+0.51%)
Ardelyx to Report Third Quarter 2025 Financial Results on October 30, 2025

WALTHAM, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines...

ARDX : 5.86 (+0.51%)
Ardelyx Appoints Experienced Finance Executive, Sue Hohenleitner, as Chief Financial Officer

WALTHAM, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines...

ARDX : 5.86 (+0.51%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Ardelyx, Inc. is a clinical-stage biopharmaceutical company. It discovers, develops and commercializes small molecule therapeutics that work in the gastrointestinal tract to treat cardio-renal, GI and metabolic diseases. The Company's lead product candidate is Tenapanor which is in three ongoing Phase...

See More

Key Turning Points

3rd Resistance Point 6.21
2nd Resistance Point 6.08
1st Resistance Point 5.97
Last Price 5.86
1st Support Level 5.73
2nd Support Level 5.60
3rd Support Level 5.49

See More

52-Week High 6.78
Last Price 5.86
Fibonacci 61.8% 5.42
Fibonacci 50% 4.99
Fibonacci 38.2% 4.57
52-Week Low 3.21

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar